StockNews.AI
ONC
StockNews.AI
3 days

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

1. ONC to present strong new data on BRUKINSA for CLL at ASCO. 2. Findings highlight efficacy across high-risk patient types.

2 mins saved
Full Article

FAQ

Why Bullish?

Positive data presentation can enhance investor confidence, similar to past oncology drug successes.

How important is it?

The presentation of new efficacy data at a major oncology conference could significantly influence stock performance.

Why Short Term?

Immediate market reactions expected post-presentation, influenced by investor sentiment toward the data.

Related Companies

BRLNZTSCELG
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (A.

Related News